{
  "id": "5b4c5d81-64cc-41f6-bedc-46b004eb700e",
  "title": "American Vanguard director Macicek buys $71,640 in stock",
  "link": "https://www.investing.com/news/insider-trading-news/american-vanguard-director-macicek-buys-71640-in-stock-93CH-3729212",
  "description": "",
  "author": "Investing.com",
  "published": "2024-11-19 00:56:41",
  "source": "https://www.investing.com/rss/news.rss",
  "categories": null,
  "byline": "Investing.com",
  "length": 3208,
  "excerpt": "American Vanguard director Macicek buys $71,640 in stock",
  "siteName": "Investing.com",
  "favicon": "",
  "text": "In a recent filing with the Securities and Exchange Commission, Steven D. Macicek, a director at American Vanguard Corp (NYSE:), disclosed the purchase of 12,000 shares of the company's common stock. The shares were acquired on November 15 at a price of $5.97 each, amounting to a total transaction value of $71,640. Following this acquisition, Macicek holds a total of 31,218 shares in the company. The transaction reflects Macicek's direct ownership of the shares. In other recent news, American Vanguard Corp. has released an optimistic outlook for 2024 during its recent Third Quarter Earnings Call. The executives, led by acting CEO Tim Donnelly, confirmed an adjusted EBITDA target for 2024, between $40 million to $50 million, with sales goals set from $565 million to $580 million. The company experienced a decrease in sales of Aztec and Folex products, but offset this with a 17% increase in non-crop business sales. American Vanguard also revealed plans for a new customer-centric organizational structure to be implemented early next year. Despite facing pressures from generic competitors, particularly on its Folex product, the company remains hopeful due to a strong fourth quarter, traditionally favorable for crop protection products. Management anticipates a 15% adjusted EBITDA margin across the agricultural cycle post-transformation. The company also expects savings from improved vendor management in raw materials and logistics procurement to double to $6 million annually. These recent developments underscore American Vanguard's strategic response to current challenges and its focus on long-term growth and operational efficiency. InvestingPro Insights The recent insider purchase by Steven D. Macicek aligns with several positive indicators for American Vanguard Corp (NYSE:AVD). According to InvestingPro data, the company's stock is currently trading at $6.06, which is 43.07% of its 52-week high, suggesting potential room for growth. This insider buy comes at a time when the stock has shown strong performance in the short term, with a 12.64% price total return over the past month. InvestingPro Tips highlight that American Vanguard has maintained dividend payments for 29 consecutive years, demonstrating a commitment to shareholder returns despite recent challenges. The company's current dividend yield stands at 1.95%, which may be attractive to income-focused investors. Additionally, analysts predict that the company will return to profitability this year, which could be a catalyst for stock price appreciation. It's worth noting that the stock's Price to Book ratio of 0.53 indicates that the company may be undervalued relative to its assets. This metric, combined with the insider purchase, could signal confidence in the company's intrinsic value and future prospects. For investors seeking a more comprehensive analysis, InvestingPro offers additional insights with 7 more tips available for American Vanguard Corp. These tips could provide valuable context for understanding the company's financial health and market position in greater detail. This article was generated with the support of AI and reviewed by an editor. For more information see our T\u0026C.",
  "image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv id=\"article\"\u003e\n\u003cp\u003eIn a recent filing with the Securities and Exchange Commission, Steven D. Macicek, a director at \u003cspan itemscope=\"\" itemtype=\"http://schema.org/Corporation\"\u003e\u003cspan itemprop=\"name\"\u003e American Vanguard Corp \u003c/span\u003e\u003c/span\u003e (NYSE:), disclosed the purchase of 12,000 shares of the company\u0026#39;s common stock. The shares were acquired on November 15 at a price of $5.97 each, amounting to a total transaction value of $71,640. Following this acquisition, Macicek holds a total of 31,218 shares in the company. The transaction reflects Macicek\u0026#39;s direct ownership of the shares.\u003c/p\u003e\n\n\n\u003cp\u003eIn other recent news, American Vanguard Corp. has released an optimistic outlook for 2024 during its recent Third Quarter Earnings Call. The executives, led by acting CEO Tim Donnelly, confirmed an adjusted EBITDA target for 2024, between $40 million to $50 million, with sales goals set from $565 million to $580 million. The company experienced a decrease in sales of Aztec and Folex products, but offset this with a 17% increase in non-crop business sales. \u003c/p\u003e\n\u003cp\u003eAmerican Vanguard also revealed plans for a new customer-centric organizational structure to be implemented early next year. Despite facing pressures from generic competitors, particularly on its Folex product, the company remains hopeful due to a strong fourth quarter, traditionally favorable for crop protection products. \u003c/p\u003e\n\u003cp\u003eManagement anticipates a 15% adjusted EBITDA margin across the agricultural cycle post-transformation. The company also expects savings from improved vendor management in raw materials and logistics procurement to double to $6 million annually. These recent developments underscore American Vanguard\u0026#39;s strategic response to current challenges and its focus on long-term growth and operational efficiency.\u003c/p\u003e\n\u003ch2\u003eInvestingPro Insights\u003c/h2\u003e\n\u003cp\u003eThe recent insider purchase by Steven D. Macicek aligns with several positive indicators for American Vanguard Corp (NYSE:AVD). According to InvestingPro data, the company\u0026#39;s stock is currently trading at $6.06, which is 43.07% of its 52-week high, suggesting potential room for growth. This insider buy comes at a time when the stock has shown strong performance in the short term, with a 12.64% price total return over the past month.\u003c/p\u003e\n\u003cp\u003eInvestingPro Tips highlight that American Vanguard has maintained dividend payments for 29 consecutive years, demonstrating a commitment to shareholder returns despite recent challenges. The company\u0026#39;s current dividend yield stands at 1.95%, which may be attractive to income-focused investors. Additionally, analysts predict that the company will return to profitability this year, which could be a catalyst for stock price appreciation.\u003c/p\u003e\n\u003cp\u003eIt\u0026#39;s worth noting that the stock\u0026#39;s Price to Book ratio of 0.53 indicates that the company may be undervalued relative to its assets. This metric, combined with the insider purchase, could signal confidence in the company\u0026#39;s intrinsic value and future prospects.\u003c/p\u003e\n\u003cp\u003eFor investors seeking a more comprehensive analysis, \u003ca href=\"https://www.investing.com/pro/pricing?referral=inv_in_article_anchor\"\u003eInvestingPro\u003c/a\u003e offers additional insights with 7 more tips available for American Vanguard Corp. These tips could provide valuable context for understanding the company\u0026#39;s financial health and market position in greater detail.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eThis article was generated with the support of AI and reviewed by an editor. For more information see our T\u0026amp;C.\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "4 min read",
  "publishedTime": "2024-11-19T00:56:41Z",
  "modifiedTime": null
}
